Unlock instant, AI-driven research and patent intelligence for your innovation.

Hepatitis B virus assembly effector

A composition and drug technology, applied in the field of hepatitis B virus assembly effector, can solve problems such as poor tolerance and side effects of interferon alpha

Inactive Publication Date: 2019-06-14
INDIANA UNIV RES & TECH CORP
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Interferon alfa has severe side effects and is poorly tolerated by patients, making it a limited therapeutic strategy with success in only a small number of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hepatitis B virus assembly effector
  • Hepatitis B virus assembly effector
  • Hepatitis B virus assembly effector

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1- 1

[0120] Example 1 - Synthesis of General Intermediates 6 and 13

[0121] Synthesis of 6-methyl-2-(piperazin-1-yl)-N-(p-tolyl)pyrimidin-4-amine (6)-general intermediate:

[0122]

[0123] Synthesis of 2-chloro-6-methyl-N-(p-tolyl)pyrimidin-4-amine (3):

[0124]

[0125] Under argon, CH 3 To a solution of CN (5 mL) was added p-toluidine 2 (473 mg, 4.41 mmol) and triethylamine (0.77 mL, 5.52 mmol); the mixture was warmed to 80° C. and stirred for 24 h. The reaction was monitored by TLC; after the reaction was complete, the volatiles were removed in vacuo to give crude product. The crude product was purified by silica gel column chromatography using 10% ethyl acetate (EtOAc) / hexanes to afford compound 3 (300 mg, 35%) as an off-white solid. TLC: 20% EtOAc / hexane (R f :0.4); 1 H-NMR (DMSO-d 6 ,400MHz): δ9.76(s,1H),7.42(d,J=8.0Hz,2H),7.16(d,J=8.4Hz,2H),6.52(s,1H), 2.27(s,3H) ,2.25(s,3H).

[0126] Synthesis of tert-butyl 4-(4-methyl-6-(p-tolylamino)pyrimidin-2-yl)piperazi...

Embodiment 2

[0146] Synthesis of embodiment 2-target compound 1-22

[0147] Intermediates 6 and 13 were converted to final products by using commercially available sulfonyl chlorides or by using the sulfonyl chlorides prepared in typical Procedure A, the results are collected in Table 1 below.

[0148] Typical Procedure A: Addition of compound 6 (40 mg, 0.14 mmol) to CH under argon at 0 °C with stirring 2 Cl 2 (5mL) solution was added pyridine (0.06mL, 0.70mmol) and sulfuryl chloride (29.5mg, 0.15mmol); warmed to room temperature and stirred for 4h. The reaction was monitored by TLC; after the reaction was complete, the reaction mixture was washed with CH 2 Cl 2 (30 mL), diluted with water (15 mL), 1N HCl (10 mL), 10% NaHCO 3 The solution (15 mL), washed with brine (15 mL), dried over sodium sulfate, filtered and concentrated in vacuo to give the crude product. The precipitated material is directly purified by vacuum drying or trituration or by column chromatography to give the desire...

Embodiment 3

[0159] Synthesis of embodiment 3-target compounds 23 and 24

[0160]

[0161] Synthesis of 6-methyl-2-(4-((4-nitrophenyl)sulfonylpiperazin-1-yl)-N-(p-tolyl)pyrimidin-4-amine (64): under argon , at 0°C to CH 2 Cl 2 (5mL) solution was added pyridine (0.15mL, 1.76mmol) and 4-nitrobenzenesulfonyl chloride 63 (78mg, 0.35mmol); warmed to room temperature and stirred for 4h. The reaction was monitored by TLC; after the reaction was complete, the reaction mixture was washed with CH 2 Cl 2 (30mL) diluted with 1N HCl (15mL), 10% NaHCO 3 The solution (20 mL), water (20 mL), dried over sodium sulfate, filtered and concentrated in vacuo gave crude product. The crude product was washed with diethyl ether (2x5 mL) and n-pentane (2x5 mL), and dried in vacuo to give compound 64 (110 mg, 67%) as a white solid. TLC: 5% MeOH / CH 2 Cl 2(R f :0.8); 1 H-NMR (DMSO-d 6 ,400MHz): δ9.00(s,1H),8.41(d,J=8.8Hz,2H),8.01(d,J=8.8Hz,2H),7.38(d,J=8.4Hz,2H),7.08 (d,J=8.4Hz,2H),5.86(s,1H), 3.79(t,J...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

Description

[0001] related application [0002] This application claims priority to US Provisional Patent Application No. 61 / 892,591, filed October 18, 2013, the disclosure of which is incorporated herein by reference in its entirety. [0003] statement of government support [0004] This invention was made with Government support AI067417 awarded by the National Institutes of Health. The government has certain rights in this invention. Background technique [0005] Hepatitis B (HBV) causes viral hepatitis, which can further lead to chronic liver disease and increase the risk of cirrhosis and liver cancer (hepatocellular carcinoma). Worldwide more than 2 billion people have been infected with HBV, approximately 360 million people have chronic infection, and HBV infection causes more than one million deaths each year. HBV can be transmitted by bodily fluids: from mother to child, sexually, and through blood products. Children born to HBV-positive mothers can also become infected unless...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/535A61K31/497C07D413/00
CPCA61K31/506C07D239/47C07D239/48
Inventor A.兹洛特尼克L.李小威廉.特纳S.弗朗西斯
Owner INDIANA UNIV RES & TECH CORP
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More